[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"chain-detail":3,"chain-related-ch60_F10":613,"chain-scenarios-ch60_F10":621,"chain-expert-resolve-ch60_F10":623,"chain-related":640},{"id":4,"name":5,"category":6,"groupCategory":7,"intro":8,"scale":9,"maturity":10,"meta":11,"checkState":365,"version":366,"createdBy":9,"createdAt":367,"updatedAt":368,"nodes":369},"ch60_F10","未来健康产业链","未来产业","FUTURE","再生医学、抗衰老、精准医疗、数字疗法",null,"孕育期",{"codes":12,"counts":14,"source":19,"experts":20,"isNew60":65,"shaanxi":9,"clusters":66,"maturity":10,"source60":67,"chainCode":13,"bottlenecks":68,"subCategory":321,"lifecycleStage":322,"key_technologies":323,"national_policies":333},[13],"F10",{"clusters":15,"segments":16,"companies":17,"bottlenecks":18},5,8,15,9,"全产业智慧图谱数据库（公开版）",[21,26,32,37,43,49,55,60],{"org":22,"name":23,"note":24,"title":25},"南京农业大学","周光宏","中国细胞培养肉研究开创者，主持研制国内首块细胞培养肉","教授",{"org":27,"raw":28,"name":29,"note":30,"title":31},"南京周子未来食品科技有限公司CEO、南京农业大学教授","丁世杰（南京周子未来食品科技有限公司CEO、南京农业大学教授），细胞培养肉产业化方向，推进千升级培养与中试生产","丁世杰","推进千升级培养与中试生产","细胞培养肉产业化方向",{"org":33,"raw":34,"name":35,"note":9,"title":36},"中国科学院院士、中国科学院脑科学与智能技术卓越创新中心学术主任","蒲慕明（中国科学院院士、中国科学院脑科学与智能技术卓越创新中心学术主任），神经科学基础研究与脑机接口战略布局","蒲慕明","神经科学基础研究与脑机接口战略布局",{"org":38,"raw":39,"name":40,"note":41,"title":42},"清华大学医学院教授","洪波（清华大学医学院教授），微创植入式脑机接口系统（NEO）研发，运动功能重建方向","洪波","运动功能重建方向","微创植入式脑机接口系统（NEO）研发",{"org":44,"raw":45,"name":46,"note":47,"title":48},"北京大学教授","邓宏魁（北京大学教授），化学小分子诱导多能干细胞（iPSC）技术，细胞治疗上游","邓宏魁","细胞治疗上游","化学小分子诱导多能干细胞（iPSC）技术",{"org":50,"raw":51,"name":52,"note":53,"title":54},"中国科学院上海微系统与信息技术研究所研究员","陶虎（中国科学院上海微系统与信息技术研究所研究员），柔性脑电极与植入式脑机接口技术，脑虎科技创始人","陶虎","脑虎科技创始人","柔性脑电极与植入式脑机接口技术",{"org":56,"raw":57,"name":58,"note":9,"title":59},"极麋生物创始人、CEO","曹哲厚（极麋生物创始人、CEO），细胞培养肉与新蛋白技术方向","曹哲厚","细胞培养肉与新蛋白技术方向",{"org":61,"raw":62,"name":63,"note":9,"title":64},"中国科学院脑科学与智能技术卓越创新中心研究员","赵郑拓（中国科学院脑科学与智能技术卓越创新中心研究员），侵入式脑机接口电极与系统方向","赵郑拓","侵入式脑机接口电极与系统方向",true,[],"全产业60链图谱",[69,107,126,167,185,210,240,267,290],{"name":70,"risk":71,"type":9,"status":72,"experts":73,"policies":82,"progress":95,"companies":96,"policy_support":106},"细胞培养肉无血清培养基","风险：高","已突破",[74,78],{"org":75,"raw":76,"name":23,"note":9,"title":77},"南京农业大学教授","周光宏（南京农业大学教授），培养肉培养体系研究","培养肉培养体系研究",{"org":79,"raw":80,"name":29,"note":9,"title":81},"周子未来CEO","丁世杰（周子未来CEO），无血清培养产业化","无血清培养产业化",[83,89],{"raw":84,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":88},"《关于开展生物制造中试能力建设平台培育工作的通知》（工业和信息化部办公厅、国家发展改革委办公厅，2025-06）：生物制造中试平台培育。","2025-06","关于开展生物制造中试能力建设平台培育工作的通知","工业和信息化部办公厅、国家发展改革委办公厅","生物制造中试平台培育。",{"raw":90,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":94},"《关于完善“三新食品”安全性评价资料要求的通知》（国家食品安全风险评估中心，2024-09）：新食品原料审批要求。","2024-09","关于完善“三新食品”安全性评价资料要求的通知","国家食品安全风险评估中心","新食品原料审批要求。","周子未来、CellX低血清培养基",[97,99,101,103],{"name":98,"note":9},"上海奥浦迈生物科技股份有限公司",{"name":100,"note":9},"上海多宁生物科技股份有限公司",{"name":102,"note":9},"南京周子未来食品科技有限公司",{"name":104,"note":105},"上海食未生物科技有限公司","CellX","未来食品",{"name":108,"risk":71,"type":109,"status":72,"experts":110,"policies":114,"progress":116,"companies":117,"policy_support":125},"大体积细胞培养肉生物反应器","设备",[111],{"org":79,"raw":112,"name":29,"note":9,"title":113},"丁世杰（周子未来CEO），培养肉规模化生产","培养肉规模化生产",[115],{"raw":84,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":88},"国内千升级反应器设计",[118,120,122,124],{"name":119,"note":9},"上海东富龙科技股份有限公司",{"name":121,"note":9},"森松国际控股有限公司",{"name":123,"note":9},"楚天科技股份有限公司",{"name":102,"note":9},"生物制造",{"name":127,"risk":71,"type":9,"status":72,"experts":128,"policies":136,"progress":149,"companies":150,"policy_support":166},"脑机接口神经康复植入物",[129,132],{"org":38,"raw":130,"name":40,"note":9,"title":131},"洪波（清华大学医学院教授），NEO系统","NEO系统",{"org":133,"raw":134,"name":52,"note":9,"title":135},"中国科学院上海微系统与信息技术研究所","陶虎（中国科学院上海微系统与信息技术研究所），柔性电极与植入器件","柔性电极与植入器件",[137,143],{"raw":138,"date":139,"name":140,"doc_no":9,"issuer":141,"summary":142},"《关于推动脑机接口产业创新发展的实施意见》（工业和信息化部等七部门，2025-07）：脑机接口产业创新目标与任务。","2025-07","关于推动脑机接口产业创新发展的实施意见","工业和信息化部等七部门","脑机接口产业创新目标与任务。",{"raw":144,"date":145,"name":146,"doc_no":9,"issuer":147,"summary":148},"《神经系统类医疗服务价格项目立项指南（试行）》（国家医疗保障局，2025-03）：脑机接口相关价格项目。","2025-03","神经系统类医疗服务价格项目立项指南（试行）","国家医疗保障局","脑机接口相关价格项目。","脑虎、博睿康临床推进",[151,154,156,159,161,163],{"name":152,"note":153},"博睿康医疗科技","上海",{"name":155,"note":153},"阶梯医疗",{"name":157,"note":158},"脑虎科技","上海脑虎科技有限公司",{"name":160,"note":9},"深圳微灵医疗科技有限公司",{"name":162,"note":9},"创新医疗管理股份有限公司",{"name":164,"note":165},"浙江强脑科技有限公司","BrainCo","脑机医疗",{"name":168,"risk":169,"type":9,"status":170,"experts":171,"policies":175,"progress":178,"companies":179,"policy_support":9},"食品级低成本无血清培养基","风险：极高","依赖进口",[172],{"org":75,"raw":173,"name":23,"note":9,"title":174},"周光宏（南京农业大学教授），培养肉培养体系","培养肉培养体系",[176,177],{"raw":84,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":88},{"raw":90,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":94},"国内细胞培养肉企业（周子未来、CellX等）推进低成本无血清培养基自研与国产化，食品级培养基成本与批次稳定性仍是产业化关键",[180,181,182,184],{"name":102,"note":9},{"name":104,"note":105},{"name":183,"note":9},"极麋生物",{"name":98,"note":9},{"name":186,"risk":71,"type":187,"status":188,"experts":189,"policies":196,"progress":204,"companies":205,"policy_support":9},"千升级培养肉规模化放大工艺","工艺技术","部分突破",[190,193],{"org":79,"raw":191,"name":29,"note":9,"title":192},"丁世杰（周子未来CEO），培养肉规模化放大","培养肉规模化放大",{"org":75,"raw":194,"name":23,"note":9,"title":195},"周光宏（南京农业大学教授），培养肉技术体系","培养肉技术体系",[197,198],{"raw":84,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":88},{"raw":199,"date":200,"name":201,"doc_no":9,"issuer":202,"summary":203},"《关于开展2026年生物制造标志性产品征集工作的通知》（工业和信息化部办公厅，2026-09）：生物制造标志性产品征集。","2026-09","关于开展2026年生物制造标志性产品征集工作的通知","工业和信息化部办公厅","生物制造标志性产品征集。","2025年12月周子未来建成国内最大细胞培养肉中试工厂并实现全球首次2000升生物反应器细胞培养猪肉规模化试生产（年产10-50吨）；CellX 2023年建成中国首个千升吨级中试工厂",[206,207,208,209],{"name":102,"note":9},{"name":104,"note":105},{"name":183,"note":9},{"name":121,"note":9},{"name":211,"risk":71,"type":9,"status":188,"experts":212,"policies":220,"progress":228,"companies":229,"policy_support":239},"高通道柔性神经电极与植入式脑机接口芯片",[213,216],{"org":133,"raw":214,"name":52,"note":9,"title":215},"陶虎（中国科学院上海微系统与信息技术研究所），柔性电极技术","柔性电极技术",{"org":217,"raw":218,"name":63,"note":9,"title":219},"中国科学院脑智卓越创新中心","赵郑拓（中国科学院脑智卓越创新中心），侵入式脑机接口系统","侵入式脑机接口系统",[221,222],{"raw":138,"date":139,"name":140,"doc_no":9,"issuer":141,"summary":142},{"raw":223,"date":224,"name":225,"doc_no":9,"issuer":226,"summary":227},"《采用脑机接口技术的医疗器械 术语》行业标准（国家药品监督管理局，2025-09）：脑机接口医疗器械术语标准。","2025-09","采用脑机接口技术的医疗器械 术语","国家药品监督管理局","脑机接口医疗器械术语标准。","脑虎科技硬膜下柔性电极产品、阶梯医疗高通量柔性电极产品已进入临床阶段（部分进入国家创新医疗器械特别审查程序）；高通道采集与无线传输芯片长期依赖进口",[230,231,232,233,235,237],{"name":157,"note":158},{"name":155,"note":153},{"name":160,"note":9},{"name":234,"note":9},"北京芯智达神经技术有限公司",{"name":236,"note":9},"上海智冉医疗科技有限公司",{"name":238,"note":9},"北京领创医谷科技有限公司","《上海市脑机接口未来产业培育行动方案（2025—2030年）》",{"name":241,"risk":71,"type":187,"status":188,"experts":242,"policies":246,"progress":257,"companies":258,"policy_support":9},"iPSC定向分化与规模化制备",[243],{"org":44,"raw":244,"name":46,"note":9,"title":245},"邓宏魁（北京大学教授），iPSC诱导与定向分化技术","iPSC诱导与定向分化技术",[247,252],{"raw":248,"date":224,"name":249,"doc_no":9,"issuer":250,"summary":251},"《生物医学新技术临床研究和临床转化应用管理条例》（国务院，2025-09）：生物医学新技术临床研究与转化管理。","生物医学新技术临床研究和临床转化应用管理条例","国务院","生物医学新技术临床研究与转化管理。",{"raw":253,"date":254,"name":255,"doc_no":9,"issuer":226,"summary":256},"《关于优化细胞与基因治疗药品审评审批有关事项的公告（征求意见稿）》（国家药品监督管理局，2026-07）：细胞治疗药品审评审批优化。","2026-07","关于优化细胞与基因治疗药品审评审批有关事项的公告（征求意见稿）","细胞治疗药品审评审批优化。","国内iPSC细胞治疗企业（如跃赛生物）推进神经系统疾病等管线研发，高效定向分化、规模化扩增与致瘤性控制仍需突破",[259,261,264],{"name":260,"note":9},"中盛溯源生物科技有限公司",{"name":262,"note":263},"士泽生物医药","苏州",{"name":265,"note":266},"霍德生物","杭州霍德生物技术有限公司",{"name":268,"risk":269,"type":187,"status":188,"experts":270,"policies":276,"progress":279,"companies":280,"policy_support":289},"HMO等合成生物食品原料审批与规模化产能","风险：中",[271],{"org":272,"raw":273,"name":274,"note":9,"title":275},"一兮生物创始人、CEO","刘振云（一兮生物创始人、CEO），HMO产业化方向","刘振云","HMO产业化方向",[277,278],{"raw":90,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":94},{"raw":199,"date":200,"name":201,"doc_no":9,"issuer":202,"summary":203},"国内合成生物学企业（弈柯莱、一兮生物等）布局2'-FL等HMO生产，相关原料按新食品原料程序推进审批",[281,284,286],{"name":282,"note":283},"一兮生物","黄山同兮生物科技有限公司",{"name":285,"note":153},"弈柯莱生物科技",{"name":287,"note":288},"恒鲁生物","青岛恒鲁生物科技有限公司","国家卫健委新食品原料审批制度",{"name":291,"risk":71,"type":187,"status":188,"experts":292,"policies":296,"progress":309,"companies":310,"policy_support":9},"实体瘤CAR-T与通用型（异体）细胞治疗",[293],{"org":44,"raw":294,"name":46,"note":9,"title":295},"邓宏魁（北京大学教授），基因编辑与细胞治疗上游技术","基因编辑与细胞治疗上游技术",[297,300,306],{"raw":298,"date":254,"name":255,"doc_no":9,"issuer":226,"summary":299},"《关于优化细胞与基因治疗药品审评审批有关事项的公告（征求意见稿）》（国家药品监督管理局，2026-07）：CGT药品审评审批优化。","CGT药品审评审批优化。",{"raw":301,"date":302,"name":303,"doc_no":9,"issuer":304,"summary":305},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国务院办公厅，2025-01）：药械监管改革支持创新。","2025-01","国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见","国务院办公厅","药械监管改革支持创新。",{"raw":307,"date":224,"name":249,"doc_no":9,"issuer":250,"summary":308},"《生物医学新技术临床研究和临床转化应用管理条例》（国务院，2025-09）：细胞治疗等新技术转化管理。","细胞治疗等新技术转化管理。","国内已有CAR-T产品获批上市（复星凯瑞奕凯达等），实体瘤靶点与通用型（异体）细胞治疗仍处临床研究阶段",[311,313,315,318],{"name":312,"note":9},"科济药业控股有限公司",{"name":314,"note":9},"亘喜生物",{"name":316,"note":317},"北恒生物","南京北恒生物科技有限公司",{"name":319,"note":320},"邦耀生物","上海邦耀生物科技有限公司","未来健康（再生医学、精准医疗）","GESTATION",[324,325,326,327,328,329,330,331,332],{"risk":71,"tech":70,"type":9,"status":72,"bottleneck":65,"domestic_status":95},{"risk":71,"tech":108,"type":109,"status":72,"bottleneck":65,"domestic_status":116},{"risk":71,"tech":127,"type":9,"status":72,"bottleneck":65,"domestic_status":149},{"risk":169,"tech":168,"type":9,"status":170,"bottleneck":65,"domestic_status":178},{"risk":71,"tech":186,"type":187,"status":188,"bottleneck":65,"domestic_status":204},{"risk":71,"tech":211,"type":9,"status":188,"bottleneck":65,"domestic_status":228},{"risk":71,"tech":241,"type":187,"status":188,"bottleneck":65,"domestic_status":257},{"risk":269,"tech":268,"type":187,"status":188,"bottleneck":65,"domestic_status":279},{"risk":71,"tech":291,"type":187,"status":188,"bottleneck":65,"domestic_status":309},[334,337,340,344,347,350,353,356,359,362],{"raw":335,"date":139,"name":140,"doc_no":9,"issuer":141,"summary":336},"《关于推动脑机接口产业创新发展的实施意见》（工业和信息化部等七部门，2025-07）：首个脑机接口国家级产业政策，提出2027年、2030年产业发展目标与重点任务。","首个脑机接口国家级产业政策，提出2027年、2030年产业发展目标与重点任务。",{"raw":338,"date":145,"name":146,"doc_no":9,"issuer":147,"summary":339},"《神经系统类医疗服务价格项目立项指南（试行）》（国家医疗保障局，2025-03）：统一神经系统类医疗服务价格项目，为脑机接口等新技术临床应用明确收费路径。","统一神经系统类医疗服务价格项目，为脑机接口等新技术临床应用明确收费路径。",{"raw":341,"date":139,"name":342,"doc_no":9,"issuer":226,"summary":343},"《关于优化全生命周期监管支持高端医疗器械创新发展的举措》（国家药品监督管理局，2025-07）：优化高端医疗器械审评审批与全生命周期监管，支持脑机接口、人工智能医疗器械等创新产品。","关于优化全生命周期监管支持高端医疗器械创新发展的举措","优化高端医疗器械审评审批与全生命周期监管，支持脑机接口、人工智能医疗器械等创新产品。",{"raw":345,"date":224,"name":225,"doc_no":9,"issuer":226,"summary":346},"《采用脑机接口技术的医疗器械 术语》行业标准（国家药品监督管理局，2025-09）：首个脑机接口医疗器械行业标准，统一术语体系。","首个脑机接口医疗器械行业标准，统一术语体系。",{"raw":348,"date":302,"name":303,"doc_no":9,"issuer":304,"summary":349},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国务院办公厅，2025-01）：国办发〔2024〕53号，深化药品医疗器械审评审批改革，支持创新药械发展。","国办发〔2024〕53号，深化药品医疗器械审评审批改革，支持创新药械发展。",{"raw":351,"date":224,"name":249,"doc_no":9,"issuer":250,"summary":352},"《生物医学新技术临床研究和临床转化应用管理条例》（国务院，2025-09）：规范细胞治疗等生物医学新技术临床研究与转化应用管理，自2026年5月1日起施行。","规范细胞治疗等生物医学新技术临床研究与转化应用管理，自2026年5月1日起施行。",{"raw":354,"date":254,"name":255,"doc_no":9,"issuer":226,"summary":355},"《关于优化细胞与基因治疗药品审评审批有关事项的公告（征求意见稿）》（国家药品监督管理局，2026-07）：优化细胞与基因治疗药品注册审评审批程序并公开征求意见。","优化细胞与基因治疗药品注册审评审批程序并公开征求意见。",{"raw":357,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":358},"《关于开展生物制造中试能力建设平台培育工作的通知》（工业和信息化部办公厅、国家发展改革委办公厅，2025-06）：培育生物制造中试能力建设平台，打通实验室成果到产业化的中试环节。","培育生物制造中试能力建设平台，打通实验室成果到产业化的中试环节。",{"raw":360,"date":200,"name":201,"doc_no":9,"issuer":202,"summary":361},"《关于开展2026年生物制造标志性产品征集工作的通知》（工业和信息化部办公厅，2026-09）：征集遴选生物制造标志性产品，推动合成生物等新技术产品产业化应用。","征集遴选生物制造标志性产品，推动合成生物等新技术产品产业化应用。",{"raw":363,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":364},"《关于完善“三新食品”安全性评价资料要求的通知》（国家食品安全风险评估中心，2024-09）：完善新食品原料等“三新食品”安全性评价资料要求与申报流程。","完善新食品原料等“三新食品”安全性评价资料要求与申报流程。","VERIFIED",1,"2026-10-11T22:08:50.411Z","2026-10-14T07:01:43.847Z",[370,408,435,459,496,531,570,591],{"id":371,"chainId":4,"layer":372,"segment":373,"name":373,"keyPoints":374,"companies":375,"sortOrder":382,"isKey":65,"checkState":365,"meta":383,"createdAt":406,"links":407},"cnH_F10_01","中游","细胞培养肉\u002F替代蛋白","细胞培养肉 植物蛋白 微生物蛋白",[376,377,378,379],{"name":102,"note":9},{"name":104,"note":105},{"name":183,"note":9},{"name":380,"note":381},"珍肉","北京",0,{"source":19,"experts":384,"policies":395,"chainCode":13,"aggregationZones":405},[385,388,392],{"org":75,"raw":386,"name":23,"note":9,"title":387},"周光宏（南京农业大学教授），细胞培养肉研究开创者","细胞培养肉研究开创者",{"org":389,"raw":390,"name":29,"note":9,"title":391},"周子未来CEO、南京农业大学教授","丁世杰（周子未来CEO、南京农业大学教授），培养肉产业化","培养肉产业化",{"org":56,"raw":393,"name":58,"note":9,"title":394},"曹哲厚（极麋生物创始人、CEO），培养肉与新蛋白","培养肉与新蛋白",[396,399,402],{"raw":397,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":398},"《关于开展生物制造中试能力建设平台培育工作的通知》（工业和信息化部办公厅、国家发展改革委办公厅，2025-06）：培育生物制造中试平台。","培育生物制造中试平台。",{"raw":400,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":401},"《关于完善“三新食品”安全性评价资料要求的通知》（国家食品安全风险评估中心，2024-09）：新食品原料申报与安全性评价要求。","新食品原料申报与安全性评价要求。",{"raw":403,"date":200,"name":201,"doc_no":9,"issuer":202,"summary":404},"《关于开展2026年生物制造标志性产品征集工作的通知》（工业和信息化部办公厅，2026-09）：征集生物制造标志性产品。","征集生物制造标志性产品。",[],"2026-10-12T14:28:51.882Z",[],{"id":409,"chainId":4,"layer":372,"segment":410,"name":410,"keyPoints":411,"companies":412,"sortOrder":366,"isKey":420,"checkState":365,"meta":421,"createdAt":433,"links":434},"cnH_F10_02","合成生物食品","合成奶 HMO母乳低聚糖 无动物蛋\u002F奶",[413,414,416,418],{"name":282,"note":283},{"name":415,"note":9},"蘑米生物",{"name":417,"note":9},"上海昌进生物医药科技有限公司",{"name":419,"note":9},"安徽华恒生物科技股份有限公司",false,{"source":19,"experts":422,"policies":426,"chainCode":13,"aggregationZones":432},[423],{"org":272,"raw":424,"name":274,"note":9,"title":425},"刘振云（一兮生物创始人、CEO），合成生物学与HMO产业化方向","合成生物学与HMO产业化方向",[427,430,431],{"raw":428,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":429},"《关于完善“三新食品”安全性评价资料要求的通知》（国家食品安全风险评估中心，2024-09）：新食品原料审批通道要求。","新食品原料审批通道要求。",{"raw":84,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":88},{"raw":199,"date":200,"name":201,"doc_no":9,"issuer":202,"summary":203},[],"2026-10-12T14:28:51.886Z",[],{"id":436,"chainId":4,"layer":372,"segment":437,"name":437,"keyPoints":438,"companies":439,"sortOrder":449,"isKey":420,"checkState":365,"meta":450,"createdAt":457,"links":458},"cnH_F10_03","精准营养与功能食品","个性化营养 功能性食品 益生菌",[440,442,444,446],{"name":441,"note":9},"汤臣倍健股份有限公司",{"name":443,"note":9},"华熙生物科技股份有限公司",{"name":445,"note":9},"仙乐健康科技股份有限公司",{"name":447,"note":448},"嘉必优生物技术","武汉",2,{"source":19,"experts":451,"policies":452,"chainCode":13,"aggregationZones":456},[],[453],{"raw":454,"date":91,"name":92,"doc_no":9,"issuer":93,"summary":455},"《关于完善“三新食品”安全性评价资料要求的通知》（国家食品安全风险评估中心，2024-09）：功能食品原料审批要求。","功能食品原料审批要求。",[],"2026-10-12T14:28:51.890Z",[],{"id":460,"chainId":4,"layer":372,"segment":461,"name":461,"keyPoints":462,"companies":463,"sortOrder":477,"isKey":65,"checkState":365,"meta":478,"createdAt":494,"links":495},"cnH_F10_04","细胞与基因治疗药物","CGT 基因编辑治疗 mRNA药物",[464,466,469,472,473,476],{"name":465,"note":9},"复星凯特生物科技有限公司",{"name":467,"note":468},"药明巨诺","上海药明巨诺生物科技有限公司",{"name":470,"note":471},"传奇生物","南京传奇生物科技有限公司",{"name":312,"note":9},{"name":474,"note":475},"驯鹿生物","南京驯鹿生物技术有限公司",{"name":314,"note":9},3,{"source":19,"experts":479,"policies":483,"chainCode":13,"aggregationZones":493},[480],{"org":44,"raw":481,"name":46,"note":9,"title":482},"邓宏魁（北京大学教授），iPSC与细胞治疗上游技术","iPSC与细胞治疗上游技术",[484,487,490],{"raw":485,"date":302,"name":303,"doc_no":9,"issuer":304,"summary":486},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国务院办公厅，2025-01）：深化药械审评审批改革。","深化药械审评审批改革。",{"raw":488,"date":224,"name":249,"doc_no":9,"issuer":250,"summary":489},"《生物医学新技术临床研究和临床转化应用管理条例》（国务院，2025-09）：细胞治疗等新技术临床研究与转化管理。","细胞治疗等新技术临床研究与转化管理。",{"raw":491,"date":254,"name":255,"doc_no":9,"issuer":226,"summary":492},"《关于优化细胞与基因治疗药品审评审批有关事项的公告（征求意见稿）》（国家药品监督管理局，2026-07）：优化CGT药品审评审批程序。","优化CGT药品审评审批程序。",[],"2026-10-12T14:28:51.893Z",[],{"id":497,"chainId":4,"layer":372,"segment":498,"name":498,"keyPoints":499,"companies":500,"sortOrder":508,"isKey":420,"checkState":365,"meta":509,"createdAt":529,"links":530},"cnH_F10_05","脑机接口医疗康复","植入式BCI 神经调控 假肢控制",[501,502,503,504,505,506],{"name":152,"note":153},{"name":155,"note":153},{"name":157,"note":158},{"name":160,"note":9},{"name":164,"note":165},{"name":507,"note":9},"三博脑科医院管理集团股份有限公司",4,{"source":19,"experts":510,"policies":518,"chainCode":13,"aggregationZones":528},[511,514,517],{"org":38,"raw":512,"name":40,"note":9,"title":513},"洪波（清华大学医学院教授），NEO微创植入系统","NEO微创植入系统",{"org":133,"raw":515,"name":52,"note":9,"title":516},"陶虎（中国科学院上海微系统与信息技术研究所），柔性电极与植入式接口","柔性电极与植入式接口",{"org":217,"raw":218,"name":63,"note":9,"title":219},[519,522,525],{"raw":520,"date":139,"name":140,"doc_no":9,"issuer":141,"summary":521},"《关于推动脑机接口产业创新发展的实施意见》（工业和信息化部等七部门，2025-07）：脑机接口产业创新发展目标与任务。","脑机接口产业创新发展目标与任务。",{"raw":523,"date":145,"name":146,"doc_no":9,"issuer":147,"summary":524},"《神经系统类医疗服务价格项目立项指南（试行）》（国家医疗保障局，2025-03）：脑机接口等神经系统诊疗价格项目。","脑机接口等神经系统诊疗价格项目。",{"raw":526,"date":139,"name":342,"doc_no":9,"issuer":226,"summary":527},"《关于优化全生命周期监管支持高端医疗器械创新发展的举措》（国家药品监督管理局，2025-07）：支持脑机接口等高端医疗器械创新。","支持脑机接口等高端医疗器械创新。",[],"2026-10-12T14:28:51.896Z",[],{"id":532,"chainId":4,"layer":533,"segment":534,"name":534,"keyPoints":535,"companies":536,"sortOrder":15,"isKey":420,"checkState":365,"meta":550,"createdAt":568,"links":569},"cnH_F10_06","下游","智慧医疗与AI诊断","AI诊断 数字疗法 远程医疗",[537,539,541,543,546,548],{"name":538,"note":9},"上海联影智能医疗科技有限公司",{"name":540,"note":381},"数坤科技",{"name":542,"note":9},"推想医疗科技股份有限公司",{"name":544,"note":545},"深睿医疗","北京深睿博联科技有限责任公司",{"name":547,"note":9},"医策科技",{"name":549,"note":9},"深圳迈瑞生物医疗电子股份有限公司",{"source":19,"experts":551,"policies":562,"chainCode":13,"aggregationZones":567},[552,557],{"org":553,"raw":554,"name":555,"note":9,"title":556},"上海科技大学教授、联影智能联合创始人","沈定刚（上海科技大学教授、联影智能联合创始人），医学影像人工智能方向","沈定刚","医学影像人工智能方向",{"org":558,"raw":559,"name":560,"note":9,"title":561},"数坤科技创始人","毛新生（数坤科技创始人），医学影像AI（心脑血管）方向","毛新生","医学影像AI（心脑血管）方向",[563,566],{"raw":564,"date":139,"name":342,"doc_no":9,"issuer":226,"summary":565},"《关于优化全生命周期监管支持高端医疗器械创新发展的举措》（国家药品监督管理局，2025-07）：支持人工智能医疗器械等创新产品。","支持人工智能医疗器械等创新产品。",{"raw":301,"date":302,"name":303,"doc_no":9,"issuer":304,"summary":305},[],"2026-10-12T14:28:51.900Z",[],{"id":571,"chainId":4,"layer":572,"segment":573,"name":573,"keyPoints":574,"companies":575,"sortOrder":582,"isKey":65,"checkState":365,"meta":583,"createdAt":589,"links":590},"cnH_F10_07","上游","生物制造装备与原料","细胞培养肉与合成生物食品依赖生物反应器、培养基、酶制剂等上游投入品，高端设备与食品级原料部分依赖进口",[576,577,578,579,580],{"name":119,"note":9},{"name":123,"note":9},{"name":121,"note":9},{"name":100,"note":9},{"name":581,"note":9},"上海乐纯生物技术股份有限公司",6,{"source":19,"experts":584,"policies":585,"chainCode":13,"aggregationZones":588},[],[586,587],{"raw":397,"date":85,"name":86,"doc_no":9,"issuer":87,"summary":398},{"raw":199,"date":200,"name":201,"doc_no":9,"issuer":202,"summary":203},[],"2026-10-12T14:28:51.903Z",[],{"id":592,"chainId":4,"layer":372,"segment":593,"name":593,"keyPoints":594,"companies":595,"sortOrder":601,"isKey":420,"checkState":365,"meta":602,"createdAt":611,"links":612},"cnH_F10_08","抗衰老与再生医学","涵盖干细胞\u002FiPSC再生医学与抗衰老相关研究与早期产业化，国内以临床研究和管线推进为主要阶段",[596,598,599,600],{"name":597,"note":9},"中源协和细胞基因工程股份有限公司",{"name":443,"note":9},{"name":262,"note":263},{"name":260,"note":9},7,{"source":19,"experts":603,"policies":607,"chainCode":13,"aggregationZones":610},[604],{"org":44,"raw":605,"name":46,"note":9,"title":606},"邓宏魁（北京大学教授），iPSC技术方向","iPSC技术方向",[608,609],{"raw":248,"date":224,"name":249,"doc_no":9,"issuer":250,"summary":251},{"raw":253,"date":254,"name":255,"doc_no":9,"issuer":226,"summary":256},[],"2026-10-12T14:28:51.907Z",[],{"chainId":4,"chainName":5,"matchedTagNames":614,"experts":615,"achievements":617,"topUniversities":619,"note":620},[],{"count":382,"items":616},[],{"count":382,"items":618},[],[],"无标签映射",{"hasMapping":420,"chainId":4,"segments":622},[],[624,626,628,630,632,634,636,638],{"name":23,"id":625},"af8cf685-06b2-4d2f-ac4c-692bbdf15f41",{"name":29,"id":627},"cmv7rhp1a006dhiky0h2xvtsh",{"name":35,"id":629},"cmv7rhp1h006ihikyqjlzcda9",{"name":40,"id":631},"cmv7rhp1m006nhikyi9xc4snb",{"name":46,"id":633},"cmv7rhp1s006shiky6yoo9714",{"name":52,"id":635},"cmv7rhp1w006xhiky9i78de8d",{"name":58,"id":637},"cmv7rhp220072hikygop15sni",{"name":63,"id":639},"cmv7rhp280077hikyv1488zhj",{"list":641,"total":17,"page":366,"pageSize":16,"totalPages":449},[642,647,653,658,664,670],{"id":643,"name":644,"category":6,"groupCategory":7,"intro":645,"scale":9,"maturity":10,"checkState":365,"nodeCount":582,"companyCount":646},"ch60_F12","元宇宙与XR产业链","VR\u002FAR\u002FMR、数字孪生、数字人、空间计算",79,{"id":648,"name":649,"category":6,"groupCategory":7,"intro":650,"scale":651,"maturity":10,"checkState":365,"nodeCount":18,"companyCount":652},"48f1ae82-a07c-4d67-93c0-abb71a5d1e0d","具身智能与人形机器人产业链","人形机器人本体、具身大模型、灵巧手、核心零部件","中国人形机器人整机企业超140家、发布产品超330款(工信部，2025)；产业整体处量产初期，市场规模待权威口径",138,{"id":654,"name":655,"category":6,"groupCategory":7,"intro":656,"scale":9,"maturity":10,"checkState":365,"nodeCount":16,"companyCount":657},"ch60_F07","可控核聚变产业链","托卡马克、高温超导、聚变堆材料",84,{"id":659,"name":660,"category":6,"groupCategory":7,"intro":661,"scale":662,"maturity":10,"checkState":365,"nodeCount":16,"companyCount":663},"f3e1775a-755b-4ffd-acaf-e4bff5f6d75b","合成生物产业链","合成生物学平台、生物制造、细胞工厂","中国生物制造产业总规模约1.1万亿元,生物发酵产品产量占全球70%以上(工信部,2025);其中食品及添加剂、生物制药两个细分领域年产值均超4000亿元",91,{"id":665,"name":666,"category":6,"groupCategory":7,"intro":667,"scale":668,"maturity":10,"checkState":365,"nodeCount":18,"companyCount":669},"deccf963-6b65-4294-9291-483b47327169","基因与生物技术产业链","基因编辑、合成生物学、生物制造","中国基因组测序市场规模约328.6亿元(灼识咨询\u002F中国医疗器械行业协会基因检测分会白皮书,2025);中国细胞与基因治疗(CGT)市场规模2025年首次突破500亿元(行业公开统计,2025)",37,{"id":671,"name":672,"category":6,"groupCategory":7,"intro":673,"scale":9,"maturity":10,"checkState":365,"nodeCount":18,"companyCount":674},"ch60_F11","未来信息产业链","光计算、存算一体、神经形态芯片",118]